Search:
Tokushima University > University Hospital > Clinical Division > Department of Internal Medicine > Hematology >
Tokushima University > Research Clusters > Research Clusters (Registered) > 1704025 個別化医療の実現に向けた,医薬品による副作用発現予測遺伝子マーカーの同定 >
Tokushima University > Faculty of Medicine > School of Medicine > Course of Molecular Medicine > Hemotology, endocrinology and metabolism >
(CSV files for researchmap) [PDF manual]

Research Activity

Field of Study

Medicine

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1. Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki and Masahiro Abe :
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.,
Oncotarget, Vol.10, No.20, 1903-1917, 2019.
(Tokushima University Institutional Repository: 113359,   DOI: 10.18632/oncotarget.26726,   PubMed: 30956773)
2. Yuko Miyakami, Shingen Nakamura, Masahiro Oura, Yasunobu Okamoto, 高橋 真美子, Kimiko Sogabe, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hisanori Uehara and Masahiro Abe :
不明熱と著明な高CRP血症で発症したde novo CD20陰性びまん性大細胞型B細胞リンパ腫の1例,
Shikoku Acta Medica, Vol.74, No.5-6, 193-200, 2018.
(Tokushima University Institutional Repository: 112987)
3. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura, Ryota Amachi, Hirofumi Tenshin, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.,
British Journal of Haematology, Vol.180, No.4, 581-585, 2018.
(Tokushima University Institutional Repository: 112935,   DOI: 10.1111/bjh.14388,   PubMed: 27748523)
4. Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe :
Effective impairment of myeloma cells and their progenitors by hyperthermia.,
Oncotarget, Vol.9, No.12, 10307-10316, 2017.
(Tokushima University Institutional Repository: 113059,   DOI: 10.18632/oncotarget.23121,   PubMed: 29535808,   Elsevier: Scopus)
5. Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.,
Blood Advances, Vol.1, No.24, 2124-2137, 2017.
(Tokushima University Institutional Repository: 113517,   DOI: 10.1182/bloodadvances.2017008813,   PubMed: 29296860)
6. Ariunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara and Masahiro Abe :
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.,
Oncotarget, Vol.7, No.48, 79064-79075, 2016.
(Tokushima University Institutional Repository: 113049,   DOI: 10.18632/oncotarget.12594,   PubMed: 27738323)
7. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Masahiro Abe and Toshio Matsumoto :
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.,
Oncotarget, Vol.7, No.43, 70447-70461, 2016.
(Tokushima University Institutional Repository: 113048,   DOI: 10.18632/oncotarget.11927,   PubMed: 27626482)
8. Takeshi Harada, Hirokazu Miki, Q Cui, A Oda, Ryota Amachi, Jumpei Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Sumiko Yoshida, I Endo, Ken-ichi Aihara, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.,
Leukemia, Vol.31, No.1, 258-262, 2016.
(DOI: 10.1038/leu.2016.273,   PubMed: 27698446)
9. Shingen Nakamura, Hirokazu Miki, Asuka Oda, Ryota Amachi, Jumpei Teramachi, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions,
International Journal of Myeloma, Vol.6, No.1, 7-11, 2015.
10. Hirokazu Miki, Shingen Nakamura, A Oda, R Amachi, Keiichiro Watanabe, D Hanson, Jumpei Teramachi, Masahiro Hiasa, H Yagi, K Sogabe, M Takahashi, T Maruhashi, K Udaka, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, M Ri, S Iida, Shuji Ozaki, T Matsumoto and Masahiro Abe :
Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death,
International Journal of Myeloma., Vol.5, No.1, 1-7, 2015.
11. Masahiro Hiasa, Jumpei Teramachi, A Oda, Ryota Amachi, T Harada, Shingen Nakamura, Hirokazu Miki, Shiroh Fujii, Kumiko Kagawa, Keiichiro Watanabe, Itsuro Endo, Y Kuroda, T Yoneda, Daisuke Tsuji, Michiyasu Nakao, Eiji Tanaka, Kenichi Hamada, Shigeki Sano, Kouji Itou, Toshio Matsumoto and Masahiro Abe :
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.,
Leukemia, 2014.
(DOI: 10.1038/leu.2014.147,   PubMed: 24787487)
12. Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Masami Iwasa, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Yoshiaki Kuroda, Shigeto Kawai, Kouji Itou, Hisafumi Yamada-Okabe, Toshio Matsumoto and Masahiro Abe :
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors,
PLoS ONE, Vol.8, No.12, e83905, 2013.
(DOI: 10.1371/journal.pone.0083905,   PubMed: 24386306,   Elsevier: Scopus)
13. Shingen Nakamura, Hirokazu Miki, Shinsuke Kido, Ayako Nakano, Masahiro Hiasa, Asuka Oda, Hiroe Amou, Keiichiro Watanabe, Takeshi Harada, Shiroh Fujii, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Activating transcription factor 4, an ER stress mediator, is required for, but exce ssive ER stress suppresses osteoblastogenesis by bortezomib.,
International Journal of Hematology, Vol.98, No.1, 66-73, 2013.
(DOI: 10.1007/s12185-013-1367-z,   PubMed: 23708974,   Elsevier: Scopus)
14. Keisuke Fujioka, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Masahiko Azuma, Kyoko Takeuchi, Shiroh Fujii, Shingen Nakamura, Kengo Utaka, Kumiko Kagawa, Masahiro Abe, Tomoya Mizutani and Yasuhiko Nishioka :
皮膚ランダム生検が診断に有用であった血管内リンパ腫の一例,
Shikoku Acta Medica, Vol.67, No.5,6, 257-262, 2011.
(Tokushima University Institutional Repository: 97858,   CiNii: 40019180117)
15. Hirokazu Miki, Shingen Nakamura, Shuji Ozaki, A Oda, H Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Q Cui, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, A Sakai, Masahiro Abe and Toshio Matsumoto :
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.,
British Journal of Haematology, Vol.155, No.3, 328-339, 2011.
(DOI: 10.1111/j.1365-2141.2011.08844.x,   PubMed: 21902681)
16. Qu Cui, Hironobu Shibata, Asuka Oda, Hiroe Amou, Ayako Nakano, Kenichiro Yata, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Targeting myeloma-osteoclast interaction with V9V2 T cells.,
International Journal of Hematology, Vol.94, No.1, 63-70, 2011.
(DOI: 10.1007/s12185-011-0885-9,   PubMed: 21698356)
17. J Asano, A Nakano, A Oda, H Amou, Masahiro Hiasa, Kyoko Takeuchi, H Miki, S Nakamura, T Harada, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Ken-ichiro Yata, A Sakai, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.,
Leukemia, 2011.
(DOI: 10.1038/leu.2011.60,   PubMed: 21475253)

Proceeding of International Conference:

1. Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe :
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy,
17th International Myeloma Workshop, Sep. 2019.
2. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Bat-Erdene Ariunzaya, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Toshio Matsumoto, Masahiro Abe and Eiji Tanaka :
Peri-implantitis and the role of Febuxostat in osteoclast differentiation.,
AEEDC Dubai World Orthodontic Conference, Dubai, UAE, Feb. 2019.
3. Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis,
60th ASH Annual Meeting & Exposition, San Diego, Dec. 2018.
4. Shingen Nakamura, Hirokazu Miki, Ariunzaya Bat-Erdene, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma.,
Esmo asia 2018, Nov. 2018.
5. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Oura Masahiro, Shingen Nakamura, Kumiko Kagawa, Okamoto Yasunobu, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis,
The 9th JSH International Symposium 2018 in Kyoto, Jul. 2018.
6. Ryota Amachi, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Jumpei Teramachi, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
Osteoblast Creates a Non-permissive Niche for Myeloma Cells,
95th General Session & Exhibition of the IADR program book, San Francisco, Mar. 2017.
7. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Pim inhibition suppresses osteoclastogenesis and tumor growth in myeloma,
57th ASH Annual Meeting and Exposition, Orlando, Dec. 2015.
8. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Asuka Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Up-regulation of the pH sensor TRPV1 in myeloma cells and their adaption to an acidic microenvironment,
ASBMR 2015 Annual Meeting, Seattle, Oct. 2015.
9. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pivotal role of TAK-1 in tumor growth and bone destruction in myeloma: Therapeutic impact of TAK-1 inhibition,
American Society for Bone and Mineral Research 2015 Annual Meeting, Oct. 2015.
10. Hirokazu Miki, Shingen Nakamura, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Effective impairment of myeloma progenitors by hyperthermia: augmentation with bortezomib and Pim inhibition in combination,
Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e217-e218, Sep. 2015.
(DOI: 10.1016/j.clml.2015.07.470)
11. Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of Pim-2 expression by clinically available anti-myeloma agents: combinatory anti-myeloma effects with Pim inhibition,
Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e243, Sep. 2015.
(DOI: 10.1016/j.clml.2015.07.517)
12. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Keiichiro Watanabe, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Critical role of Pim-2 in NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis: Therapeutic impact of Pim inhibition on myeloma bone disease.,
2014 ASBMR Annual Meeting, Houston, Sep. 2014.
13. Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, H Mori, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of bone formation in myeloma osteolytic lesions by cathepsinK inhibition,
Kyoto, Apr. 2013.
14. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, Hirokazu Miki, Shingen Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acidic milieu suppersses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression.,
Kyoto, Apr. 2013.
15. Harada Takeshi, Ozaki Shuji, Oda Asuka, Iwasa Masami, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Shibata Hironobu, Akishige Ikegame, Daisuke Tsuji, Ito Kohji, Ri Masaki, Iida Shinsuke, Shiotsu Yukimasa, Kawai Shigeto, Yamada-Okabe Hisafumi and Toshio Matsumoto :
Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012.,
The 54th Annual Meeting of the American Society of Hamatology, Dec. 2012.
16. T Harada, Shuji Ozaki, A Oda, M Iwasa, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Hirofumi Shibata, Akishige Ikegame, Daisuke Tsuji, Kouji Itou, M Ri, S Iida, Y Shiotsu, S Kawai, H Yamada-Okabe and Toshio Matsumoto :
Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells.,
54th ASH Annual Meeting and Exposition, USA, Atlanta, Dec. 2012.
17. Keiichiro Watanabe, Masahiro Abe, M Kawatani, Masahiro Hiasa, A Kawano, T Jinno, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, H Osada and Toshio Matsumoto :
Aggravation of myeloma growth and drug resistance by an acidic created in myeloma-osteoclast interaction.,
ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
18. Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition.,
ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
19. Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression.,
IOF-ANZBMS 2011 Annual Meeting, Gold Coast, Sep. 2011.
20. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
An Acidic Mileu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent,
52th American Society of Hematology, Orlando, Dec. 2010.
21. Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment,
52th American Society of Hematology, Orlando, Dec. 2010.
22. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
A Novel Anti-resorptive Agent, Reveromycin A, Ameliorates Bone Destruction and Tumor Growth in Myeloma,
ASBMR 2010 Annual Meeting, Toronto, Oct. 2010.
23. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma,
10th International Conference Cancer-induced Bone Disease, Sheffield (United Kingdom), Sep. 2010.

Proceeding of Domestic Conference:

1. Yuto Tanigaki, Yuta Yamaguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定,
日本薬学会 第139年会, Mar. 2019.
2. Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析を用いたビンクリスチンによる末梢神経障害発現関連遺伝子の同定,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
3. Yuta Yamaguchi, Yuto Tanigaki, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
CYP遺伝子多型とバンコマイシンの副作用発現及び血中濃度との関連解析,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
4. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Iwasa Masami, Shiroh Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction,
第80回日本血液学会学術集会, Oct. 2018.
5. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, Kimiko Sogabe, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果,
第80回日本血液学会学術集会, Oct. 2018.
6. Ashtar Mohannad, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Ariunzaya Erdene Bat, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
7. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
8. Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Kotaro Tanimoto, Ariunzaya Bat-Erdene, Mohannad Ashtar, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Oda Asuka, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
9. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, 前田 悠作, 高橋 真美子, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Amplification of the IFN- γ -STAT1- PD-L1 pathway in myeloma cells by panobinostat,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
10. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Maeda Yusaku, Shingen Nakamura, Oura Masahiro, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
11. Yuto Tanigaki, Youichi Sato, Yuta Yamaguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
テイコプラニン投与による副作用発現および血中濃度とCYP遺伝子多型との関連解析,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
12. Hozumi Tashima, Youichi Sato, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
シタラビン投与による副作用発現と代謝経路関連遺伝子多型の関連解析,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
13. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Oura, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.
14. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Ohhra, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.
15. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Ariunzaya Baterdene, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TRAILは破骨細胞を活性化させるが,TAK1阻害により骨髄腫細胞とともに破骨細胞にもTRAILのアポトーシス誘導活性が惹起できる,
The 35th Annual Meeting of the Japanese Society for Bone and Mineral Research (oral talk), Jul. 2017.
16. Rio Ohmori, Youichi Sato, Misaki Kiguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性,
第20回日本医薬品情報学会総会・学術大会, Jul. 2017.
17. Yuta Yamaguchi, Youichi Sato, Yuto Tanigaki, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析,
第20回日本医薬品情報学会総会・学術大会, Jul. 2017.
18. Jumpei Teramachi, Hiroshi Mori, Yasuo Ochi, Ryota Amachi, Asuka Oda, Masahiro Hiasa, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma.,
The 77th Annual Meeting of the Japanese Society of Hematology, Oct. 2016.
19. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, 遠藤 逸郎, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment.,
第77回日本血液学会学術集会,, Oct. 2016.
20. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Hirofumi Tenshin, Shingen Nakamura, Ryota Amachi, Shiroh Fujii, Keiichiro Watanabe, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim-2は骨髄腫における破骨細胞形成促進の 必須媒介因子である,
第41回日本骨髄腫学会学術集会, May 2016.
21. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, A Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, H Miki, Kumiko Kagawa, Shiroh Fujii, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment,
第77回日本血液学会学術集会, Oct. 2015.
22. Keiichiro Watanabe, Jumpei Teramachi, H Mori, Y Ochi, Ryota Amachi, A Oda, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma,
第77回日本血液学会学術集会, Oct. 2015.
23. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Potent suppression of osteoclastogenesis in myeloma by Pim inhibition,
第77回日本血液学会学術集会, Oct. 2015.
24. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Tumor reduction and bone restoration in myeloma by TAK-1 inhibition,
第77回日本血液学会学術集会, Oct. 2015.
25. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
酸環境での骨髄腫細胞のDR4発現抑制:酸によるエピジェネティックな遺伝子発現制御,
第1回日本骨免疫学会, 108, Jul. 2015.
26. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Ryota Amachi, Hirofumi Tenshin, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Pim阻害による骨髄腫骨吸収亢進の抑制,
第40回日本骨髄腫学会学術集会, May 2015.
27. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Ryota Amachi, Hirofumi Tenshin, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
TAK-1は骨髄腫腫瘍進展と骨破壊病変形成の枢軸的な媒介因子である,
第40回日本骨髄腫学会学術集会, May 2015.
28. 丸橋 朋子, Shingen Nakamura, 曽我部 公子, 八木 ひかる, 高橋 真美子, 宇高 憲吾, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Atsuro Saijo, Mayuri Nakano, Momoyo Azuma, Yasuhiko Nishioka, 近藤 憲保, 井内 新, 藤田 博己 and 馬原 文彦 :
当院で経験した重症熱性血小板減少症候群の3例,
第250回徳島医学会学術集会, Feb. 2015.
29. Jumpei Teramachi, Masahiro Hiasa, 原田 武志, Ryota Amachi, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of Pim inhibition on myeloma bone disease: blockade of NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis,
日本血液学会, Oct. 2014.
30. Keiichiro Watanabe, Masahiro Abe, H Mori, K Udaka, M Iwasa, D Hanson, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto :
Bone restoration and tumor suppression in myeloma by cathepsin K inhibition with Bortezomib,
第75回日本血液学会学術集会, Oct. 2013.
31. 大黒 由加里, Takeshi Kondo, Shiroh Fujii, Shingen Nakamura, 倉橋 清衛, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto :
著名な汎血球減少と肝筋逸脱酵素高値を呈した神経性食欲不振症の一例,
第13回日本内分泌学会四国支部学術集会, Sep. 2013.
32. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, H Miki, S Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acdic milieu confers the resistance to TRAIL in myeloma cells through the PI3K-Akt-mediated epigenetic down-regulation of the TRAIL receptor DR4,
International Bone and Mineral Society 2013, May 2013.
33. Keiichiro Watanabe, Masahiro Abe, H Mori, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, S Nakamura, H Miki, K Kagawa, I Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of cathepsin K induce bone formation in myeloma osteolytic lesions,
International Bone and Mineral Society 2013, May 2013.
34. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, H Miki, S Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acdic milieu suppresses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression,
14th International Myeloma Workshop, Apr. 2013.
35. Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, S Nakamura, H Miki, K Kagawa, I Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of bone formation in myeloma osteolytic lesions by cathepsin K inhibition,
14th International Myeloma Workshop, Apr. 2013.
36. Hirokazu Miki, Shingen Nakamura, 竹内 恭子, 原田 武志, 岩佐 昌美, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Toshio Matsumoto :
赤芽球癆を合併した多中心性Castleman病の1例,
日本内科学会第107回四国地方会, Dec. 2012.
37. Shiroh Fujii, Masahiro Abe, Ryota Amachi, Keiichiro Watanabe, Masahiro Hiasa, 竹内 恭子, 岩佐 昌美, 原田 武志, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Toshio Matsumoto :
Pim inhibition preferentially induces anti-myeloma activity in an acidic milien,
第74回日本血液学会学術集会, Oct. 2012.
38. 原田 武志, Shuji Ozaki, 岩佐 昌美, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, 柴田 泰伸, 重清 俊雄, 岡田 直人, 長尾 多美子, 鈴木 麗子, Shoji Sakiyama, Masahiro Abe and Toshio Matsumoto :
徳島県のエイズ拠点病院におけるHIV感染症及び後天性免疫不全症候群の現状,
第245回徳島県医学会学術総会, Jul. 2012.
39. 大黒 由加里, Shingen Nakamura, 岩佐 昌美, 原田 武志, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe, Toshio Matsumoto and Hirokazu Miki :
腰痛と副腎不全症状で発症した両側副腎原発DLBCLの1例,
日本内科学会第106回四国地方会, Jun. 2012.
40. 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 中野 綾子, Kumiko Kagawa, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
徳島県における多発性骨髄腫の治療成績の検討,
第109回日本内科学会総会・講演会, Apr. 2012.
41. 原田 武志, Shuji Ozaki, 小田 明日香, 天羽 宏枝, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 中野 綾子, Kumiko Kagawa, 竹内 恭子, Masahiro Abe, 柴田 泰伸 and Toshio Matsumoto :
Lenalidomide 治療中の多発性骨髄腫患者におけるCRP上昇の検討,
第51回日本血液学会中国四国地方会, Mar. 2012.
42. Kumiko Kagawa, 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
遺伝子組み替えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例,
第34回日本造血細胞移植学会, Feb. 2012.
43. Kumiko Kagawa, 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
遺伝子組み換えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例,
第34回日本造血細胞移植学会, Feb. 2012.
44. Keiichiro Watanabe, Masahiro Abe, Q Cui, Masahiro Hiasa, M Kawatani, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, A Nakano, K Kagawa, K Takeuchi, H Osada, Eiji Tanaka and Toshio Matsumoto :
Targeting an acidic microenvironment by reveromycin A to overcome drug resistance to myeloma cells and ameliorate bone disease.,
第36回日本骨髄腫研究会総会, Nov. 2011.
45. Keisuke Fujioka, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Masahiko Azuma, Yasuhiko Nishioka, Kyoko Takeuchi, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Masahiro Abe and Tomoya Mizutani :
不明熱で発症し皮膚生検が診断に有効であった血管内リンパ腫の1例,
第243回徳島医学会学術集会, Jul. 2011.
46. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
Reveromycin A prevents bone destruction and suppresses tumor growth in myeloma,
第72回日本血液学会, Dec. 2010.
47. 宇高 憲吾, Naoko Matsui, 宮本 亮介, Yuka Terasawa, Kenta Sato, Koutaro Asanuma, Yuishin Izumi, Ryuji Kaji, Shiroh Fujii, Kyoko Takeuchi, Masahiro Abe and Masafumi Harada :
多発性骨髄腫の経過中に進行性多巣性白質脳症をきたした一例,
Shikoku Acta Medica, Vol.66, No.5-6, 198, Dec. 2010.
48. Kumiko Kagawa, Jinno Tasashi, Harada Kakeshi, Cui Qu, Keiichiro Watanabe, Masahiro Hiasa, Oda Asuka, Amo Hiroe, Akishige Ikegame, Miki Hirokazu, Shiroh Fujii, Nakano Ayako, Kyoko Takeuchi, Shuji Ozaki, Masahiro Abe and Toshio Matsumoto :
Sensitization of hematopietic malignant cells to TRAIL with bortezomib and a TACE inhibitor,
第72回日本血液学会, Sep. 2010.
49. Shingen Nakamura, Masahiro Abe, Cui Qu, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Miki Hirokazu, Nakano Ayako, Oda Asuka, Amo Hiroe, Jinno Tasashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Bortezomib-induced osteoblast differentiation is hampered by excessive ER stress,
第72回日本血液学会, Sep. 2010.
50. Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Jinnno Tadashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Bone marrow stromal cells attenuate gama delta T,
第72回日本血液学会, Sep. 2010.
51. Shingen Nakamura, Masahiro Abe, Cui Qu, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, 三木 浩和, 中野 綾子, 小田 明日香, 天羽 宏枝, 神野 雅, 原田 武志, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
ボルテゾミブによる骨芽細胞分化の促進は過剰な小胞体ストレスによって抑制される,
第28回日本骨代謝学会, Jul. 2010.

Et cetera, Workshop:

1. 梶田 敬介, Shingen Nakamura, 曽我部 公子, 藤野 ひかる, 丸橋 朋子, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hiroaki Toba and 阿部 正博 :
胸腺腫瘍に合併した赤芽球癆の二例-病態解明へのアプローチ-,
第252回徳島医学会学術集会, Feb. 2016.
2. Ryota Amachi, Masahiro Abe, Keiichiro Watanabe, Kumiko Kagawa, Shiroh Fujii, 原田 武志, Hirokazu Miki, Keiichiro Watanabe, 小野 明日香, Masahiro Hiasa, Eiji Tanaka and Toshio Matsumoto :
骨髄腫の酸性環境はTRAIL受容体発現をエピジェネティックに抑制し,TRAIL抵抗性をもたらす,
第20回徳島骨代謝研究会, Nov. 2013.
3. Masahiro Hiasa, Masahiro Abe, 中野 綾子, Keiichiro Watanabe, Kyoko Takeuchi, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, 原田 武志, Shuji Ozaki, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto :
Pimキナーゼの阻害による骨髄腫の進展抑制,
癌と骨病変研究会, Nov. 2011.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)